Selvigaltin (GB1211), an orally readily available small molecule galectin-three inhibitor designed as a treatment method for liver fibrosis and cirrhosis, was evaluated to evaluate the effect of hepatic impairment on its pharmacokinetics and security to handle regulatory specifications. In detail, we used the motor vehicle control groups because the calibrator https://chesterk665whq7.vigilwiki.com/user